Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States

Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States

Key points: In a multicenter point-prevalence study, we found that the rate of supportive care was high; among those receiving COVID-19 drug therapies, adverse reactions occurred in 12% of patients. Purpose: There are currently no FDA-approved medications for the treatment of coronavirus disease 201...

Full description

Bibliographic Details
Main Authors: Badowski, M.E (Author), Beardsley, J.R (Author), Borkowski, J.L (Author), Dairem, A. (Author), Fong, K. (Author), Hale, C.M (Author), Michienzi, S.M (Author), Moore, W.J (Author), Pallotta, A.M (Author), Polisetty, R.S (Author), Postelnick, M.J (Author), Rhodes, N.J (Author), Schulz, L.T (Author), Shah, A. (Author), Spivak, E.S (Author), Srinivas, P. (Author)
Format: Article
Language:English
Published: Oxford University Press 2021
Subjects:
acute kidney failure
acutely ill patient
adolescent
Adolescent
adult
Adult
adverse drug reaction
adverse event
aged
Aged
Aged, 80 and over
antimicrobial stewardship
Antiviral Agents
antivirus agent
Article
asthma
azithromycin
blood clotting disorder
child
Child
Child, Preschool
chronic kidney failure
clinical feature
clinical trial
combination drug therapy
community hospital
comorbidity
controlled study
coronavirus disease 2019
COVID-19
creatinine
creatinine blood level
cytokine receptor antagonist
diarrhea
drug safety
drug therapy
Drug Therapy, Combination
drug utilization
Drug-Related Side Effects and Adverse Reactions
electronic health record
experimental coronavirus disease 2019
female
Female
groups by age
headache
heart arrhythmia
hospital patient
human
Humans
hydroxychloroquine
Hydroxychloroquine
hypertransaminasemia
infant
Infant
Infant, Newborn
information processing
intensive care unit
interleukin 6 antagonist
invasive ventilation
liver enzyme
lopinavir plus ritonavir
lung lavage
major clinical study
male
Male
medication safety
middle aged
Middle Aged
monotherapy
multicenter study
nasopharyngeal swab
nausea
neutropenia
newborn
observational study
oxygen consumption
oxygen therapy
pandemic
Pandemics
pediatric patient
pharmaceutical care
point prevalence
preschool child
prevalence
Prevalence
QTc interval
random sample
remdesivir
Retrospective Studies
retrospective study
sarilumab
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
supportive care
thrombocytopenia
tocilizumab
unclassified drug
United States
university hospital
very elderly
vomiting
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items